Vifor Pharma AG (XSWX:VIFN) FCF Margin % : 19.42% (As of Dec. 2021)

View and export this data going back to 2003. Start your Free Trial

What is Vifor Pharma AG FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Vifor Pharma AG's Free Cash Flow for the six months ended in Dec. 2021 was CHF188 Mil. Vifor Pharma AG's Revenue for the six months ended in Dec. 2021 was CHF965 Mil. Therefore, Vifor Pharma AG's FCF Margin % for the quarter that ended in Dec. 2021 was 19.42%.

As of today, Vifor Pharma AG's current FCF Yield % is 2.86%.

The historical rank and industry rank for Vifor Pharma AG's FCF Margin % or its related term are showing as below:

XSWX:VIFN' s FCF Margin % Range Over the Past 10 Years
Min: 0 Med: 0 Max: 16.92
Current: 16.92

During the past 13 years, the highest FCF Margin % of Vifor Pharma AG was 16.92%. The lowest was 0.00%. And the median was 0.00%.

XSWX:VIFN's FCF Margin % is not ranked
in the Drug Manufacturers industry.
Industry Median: -0.675 vs XSWX:VIFN: 16.92

Vifor Pharma AG FCF Margin % Historical Data

The historical data trend for Vifor Pharma AG's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vifor Pharma AG FCF Margin % Chart

Vifor Pharma AG Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

FCF Margin %

Get a 7-Day Free Trial

-2.18

-5.19

22.97

2.18

16.92

Vifor Pharma AG Semi-Annual Data
	Jun12	Dec12	Jun13	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21
FCF Margin %	Get a 7-Day Free Trial															34.04	1.42	2.85	14.10	19.42

Competitive Comparison of Vifor Pharma AG's FCF Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Vifor Pharma AG's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vifor Pharma AG's FCF Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Vifor Pharma AG's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Vifor Pharma AG's FCF Margin % falls into.

Vifor Pharma AG FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Vifor Pharma AG's FCF Margin for the fiscal year that ended in Dec. 2021 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2021 )	/	Revenue (A: Dec. 2021 )
	=	308.7	/	1824.6
	=	16.92 %

Vifor Pharma AG's FCF Margin for the quarter that ended in Dec. 2021 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2021 )	/	Revenue (Q: Dec. 2021 )
	=	187.5	/	965.3
	=	19.42 %

Vifor Pharma AG FCF Margin % Related Terms

Thank you for viewing the detailed overview of Vifor Pharma AG's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Vifor Pharma AG (XSWX:VIFN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Vifor Pharma AG (XSWX:VIFN) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Rechenstrasse 37, Saint Gallen, CHE, 9014

Website

https://www.viforpharma.com

Vifor Pharma AG is a specialty drug manufacturing and licensing company. It researches, develops, and produces its pharmaceutical products and markets and distributes them worldwide. Most of its sales are generated in the USA, with Europe also a strong contributor. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.

Vifor Pharma AG (XSWX:VIFN) Headlines

No Headlines